North East and North Cumbria
ICS Formulary
 
back
8 Malignant disease and immunosuppression
08-02 Drugs affecting the immune response

Shared care guidelines are available for:


Blinatumomab Blincyto®
Formulary
  • Approved for use in previously treated Philadelphia-chromosome-negative acute lymphosblastic leukaemia in line with NICE and NHS England Commissioning Policy.
  • Approved for the treatment of acute lymphoblastic leukaemia in remission with minimal residual disease activity in line with NICE
  • Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm

 
Link  NICE TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Link  NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

Red View adult BNF  View SPC online  View childrens BNF
Tepotinib Tepmetko®
Formulary
  • Approved for treating advanced non-small-cell lung cancer (NSCLC) with METex14 skipping alterations in adults in line with NICE.
Link  NICE TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations

Cytotoxic Drug  Red View adult BNF  View SPC online  View childrens BNF  HCD